input stringlengths 17 568 | output unknown | schema unknown |
|---|---|---|
Intravenous azithromycin-induced ototoxicity. | {
"entities": {
"drug": [
{
"text": "azithromycin",
"start": 12,
"end": 24
}
],
"adverse effect": [
{
"text": "ototoxicity",
"start": 33,
"end": 44
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by rifampicin, could have led to increased calcium-release into the circulation. | {
"entities": {
"drug": [
{
"text": "dihydrotachysterol",
"start": 91,
"end": 109
}
],
"adverse effect": [
{
"text": "increased calcium-release",
"start": 143,
"end": 168
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol. | {
"entities": {
"adverse effect": [
{
"text": "hypercalcemia",
"start": 21,
"end": 34
}
],
"drug": [
{
"text": "dihydrotachysterol",
"start": 84,
"end": 102
}
]
},
"relations": {
"adverse effect": [
{
"head":... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin. | {
"entities": {
"adverse effect": [
{
"text": "pseudoporphyria",
"start": 32,
"end": 47
}
],
"drug": [
{
"text": "naproxen",
"start": 58,
"end": 66
},
{
"text": "oxaprozin",
"start": 71,
"end": 80
}... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population. | {
"entities": {
"drug": [
{
"text": "Naproxen",
"start": 0,
"end": 8
}
],
"adverse effect": [
{
"text": "erythropoietic protoporphyria",
"start": 134,
"end": 163
}
]
},
"relations": {
"adverse effect": [
{
"h... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands. | {
"entities": {
"drug": [
{
"text": "naproxen",
"start": 34,
"end": 42
},
{
"text": "oxaprozin",
"start": 96,
"end": 105
}
],
"adverse effect": [
{
"text": "tense bullae",
"start": 146,
"end": 158
}... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
BACKGROUND: How to best treat psychotic patients who have had past clozapine-induced agranulocytosis or granulocytopenia remains a problem. | {
"entities": {
"drug": [
{
"text": "clozapine",
"start": 67,
"end": 76
}
],
"adverse effect": [
{
"text": "granulocytopenia",
"start": 104,
"end": 120
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSION: The results suggest that olanzapine may be useful in treating patients with clozapine-induced granulocytopenia without the risk of recurrence of hematologic side effects. | {
"entities": {
"drug": [
{
"text": "clozapine",
"start": 88,
"end": 97
}
],
"adverse effect": [
{
"text": "granulocytopenia",
"start": 106,
"end": 122
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. | {
"entities": {
"drug": [
{
"text": "5-fluorouracil",
"start": 17,
"end": 31
}
],
"adverse effect": [
{
"text": "neurotoxicity",
"start": 43,
"end": 56
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit. | {
"entities": {
"drug": [
{
"text": "5-FU",
"start": 32,
"end": 36
}
],
"adverse effect": [
{
"text": "severe mucositis",
"start": 76,
"end": 92
},
{
"text": "prolonged myelosuppression",
"start": 119,
"e... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome. | {
"entities": {
"drug": [
{
"text": "BH-AC",
"start": 24,
"end": 29
}
],
"adverse effect": [
{
"text": "encephalopathy syndrome",
"start": 135,
"end": 158
}
]
},
"relations": {
"adverse effect": [
{
"head": {... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin. | {
"entities": {
"adverse effect": [
{
"text": "encephalopathy syndrome",
"start": 31,
"end": 54
}
],
"drug": [
{
"text": "BH-AC",
"start": 180,
"end": 185
},
{
"text": "idarubicin",
"start": 239,
"end": 2... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
In one case, the readministration of riluzole was followed by the relapse of hepatitis. | {
"entities": {
"drug": [
{
"text": "riluzole",
"start": 37,
"end": 45
}
],
"adverse effect": [
{
"text": "hepatitis",
"start": 77,
"end": 86
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively. | {
"entities": {
"adverse effect": [
{
"text": "hepatitis",
"start": 56,
"end": 65
}
],
"drug": [
{
"text": "riluzole",
"start": 79,
"end": 87
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. | {
"entities": {
"adverse effect": [
{
"text": "Lupus-like syndrome",
"start": 0,
"end": 19
}
],
"drug": [
{
"text": "5-aminosalicylic acid",
"start": 30,
"end": 51
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia. | {
"entities": {
"drug": [
{
"text": "lidocaine",
"start": 111,
"end": 120
}
],
"adverse effect": [
{
"text": "methemoglobinemia",
"start": 270,
"end": 287
}
]
},
"relations": {
"adverse effect": [
{
"head": {... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field. | {
"entities": {
"adverse effect": [
{
"text": "Methemoglobinemia",
"start": 0,
"end": 17
}
],
"drug": [
{
"text": "bupivacaine",
"start": 44,
"end": 55
},
{
"text": "lidocaine",
"start": 84,
"end": 93
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field. | {
"entities": {
"adverse effect": [
{
"text": "methemoglobinemia",
"start": 111,
"end": 128
}
],
"drug": [
{
"text": "bupivacaine",
"start": 158,
"end": 169
},
{
"text": "lidocaine",
"start": 198,
"end": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient. | {
"entities": {
"drug": [
{
"text": "aspirin",
"start": 57,
"end": 64
}
],
"adverse effect": [
{
"text": "asthma",
"start": 73,
"end": 79
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer. | {
"entities": {
"adverse effect": [
{
"text": "encephalopathy",
"start": 23,
"end": 37
}
],
"drug": [
{
"text": "methotrexate",
"start": 79,
"end": 91
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported. | {
"entities": {
"drug": [
{
"text": "MTX",
"start": 65,
"end": 68
}
],
"adverse effect": [
{
"text": "neurotoxicity",
"start": 77,
"end": 90
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"te... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe a life threatening side effect of acute epoprostenol infusion (pulmonary edema) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology. | {
"entities": {
"drug": [
{
"text": "epoprostenol",
"start": 52,
"end": 64
}
],
"adverse effect": [
{
"text": "pulmonary edema",
"start": 75,
"end": 90
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone. | {
"entities": {
"adverse effect": [
{
"text": "pruritic bullous eruption",
"start": 56,
"end": 81
}
],
"drug": [
{
"text": "prednisone",
"start": 91,
"end": 101
}
]
},
"relations": {
"adverse effect": [
{
"he... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia. | {
"entities": {
"drug": [
{
"text": "Hydroxyurea",
"start": 0,
"end": 11
}
],
"adverse effect": [
{
"text": "acute interstitial pneumonitis",
"start": 20,
"end": 50
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea. | {
"entities": {
"adverse effect": [
{
"text": "interstitial pneumonitis",
"start": 38,
"end": 62
}
],
"drug": [
{
"text": "hydroxyurea",
"start": 78,
"end": 89
}
]
},
"relations": {
"adverse effect": [
{
"hea... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature. | {
"entities": {
"drug": [
{
"text": "hydroxyurea",
"start": 26,
"end": 37
}
],
"adverse effect": [
{
"text": "acute interstitial pneumonitis",
"start": 46,
"end": 76
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Allergic and irritant contact dermatitis to calcipotriol. | {
"entities": {
"adverse effect": [
{
"text": "irritant contact dermatitis",
"start": 13,
"end": 40
}
],
"drug": [
{
"text": "calcipotriol",
"start": 44,
"end": 56
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common. | {
"entities": {
"drug": [
{
"text": "Calcipotriol",
"start": 0,
"end": 12
}
],
"adverse effect": [
{
"text": "irritation of the skin",
"start": 78,
"end": 100
},
{
"text": "allergic reactions",
"start": 110,
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol. | {
"entities": {
"adverse effect": [
{
"text": "irritant type of reaction",
"start": 185,
"end": 210
}
],
"drug": [
{
"text": "calcipotriol",
"start": 232,
"end": 244
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Myotonia associated with sarcoidosis: marked exacerbation with pravastatin. | {
"entities": {
"adverse effect": [
{
"text": "Myotonia",
"start": 0,
"end": 8
}
],
"drug": [
{
"text": "pravastatin",
"start": 63,
"end": 74
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Pravastatin is associated with myotonia in animals. | {
"entities": {
"drug": [
{
"text": "Pravastatin",
"start": 0,
"end": 11
}
],
"adverse effect": [
{
"text": "myotonia",
"start": 31,
"end": 39
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans. | {
"entities": {
"drug": [
{
"text": "pravastatin",
"start": 40,
"end": 51
}
],
"adverse effect": [
{
"text": "myotonia",
"start": 171,
"end": 179
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction. | {
"entities": {
"drug": [
{
"text": "aspirin",
"start": 20,
"end": 27
}
],
"adverse effect": [
{
"text": "urticaria",
"start": 63,
"end": 72
},
{
"text": "angioedema",
"start": 80,
"end": 90
},
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSION: Fixed drug eruption is associated with many drugs but this is the first such report with omeprazole. | {
"entities": {
"adverse effect": [
{
"text": "eruption",
"start": 23,
"end": 31
}
],
"drug": [
{
"text": "omeprazole",
"start": 101,
"end": 111
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Fixed drug eruption in hands caused by omeprazole. | {
"entities": {
"adverse effect": [
{
"text": "eruption",
"start": 11,
"end": 19
}
],
"drug": [
{
"text": "omeprazole",
"start": 39,
"end": 49
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment. | {
"entities": {
"adverse effect": [
{
"text": "eruption",
"start": 65,
"end": 73
}
],
"drug": [
{
"text": "omeprazole",
"start": 95,
"end": 105
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine. | {
"entities": {
"adverse effect": [
{
"text": "diffuse erythema",
"start": 121,
"end": 137
},
{
"text": "pustules",
"start": 142,
"end": 150
},
{
"text": "malaise",
"start": 174,
"end": 181
},
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis. | {
"entities": {
"adverse effect": [
{
"text": "Acute generalized exanthematous pustulosis",
"start": 0,
"end": 42
}
],
"drug": [
{
"text": "salazosulfapyridine",
"start": 54,
"end": 73
}
]
},
"relations": {
"adverse effect... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis. | {
"entities": {
"adverse effect": [
{
"text": "acute generalized exanthematous pustulosis",
"start": 20,
"end": 62
}
],
"drug": [
{
"text": "salazosulfapyridine",
"start": 81,
"end": 100
}
]
},
"relations": {
"adverse effe... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230). | {
"entities": {
"drug": [
{
"text": "olanzapine",
"start": 72,
"end": 82
}
],
"adverse effect": [
{
"text": "elevated serum CK concentration",
"start": 96,
"end": 127
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
DISCUSSION: Olanzapine, like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin. | {
"entities": {
"drug": [
{
"text": "Olanzapine",
"start": 12,
"end": 22
}
],
"adverse effect": [
{
"text": "muscle injury with concomitant elevations of serum CK",
"start": 75,
"end": 128
}
]
},
"relations": {
"adverse ef... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Marked elevation of serum creatine kinase associated with olanzapine therapy. | {
"entities": {
"adverse effect": [
{
"text": "elevation of serum creatine kinase",
"start": 7,
"end": 41
}
],
"drug": [
{
"text": "olanzapine",
"start": 58,
"end": 68
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
OBJECTIVE: To report a case of marked elevation of serum creatine kinase (CK) associated with olanzapine therapy. | {
"entities": {
"adverse effect": [
{
"text": "elevation of serum creatine kinase",
"start": 38,
"end": 72
}
],
"drug": [
{
"text": "olanzapine",
"start": 94,
"end": 104
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Diclofenac-associated hepatitis. | {
"entities": {
"drug": [
{
"text": "Diclofenac",
"start": 0,
"end": 10
}
],
"adverse effect": [
{
"text": "hepatitis",
"start": 22,
"end": 31
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints. | {
"entities": {
"adverse effect": [
{
"text": "hepatitis",
"start": 62,
"end": 71
}
],
"drug": [
{
"text": "diclofenac",
"start": 103,
"end": 113
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
2-CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis. | {
"entities": {
"drug": [
{
"text": "2-CdA",
"start": 0,
"end": 5
}
],
"adverse effect": [
{
"text": "lymphocytopenia",
"start": 14,
"end": 29
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported. | {
"entities": {
"adverse effect": [
{
"text": "priapism",
"start": 12,
"end": 20
}
],
"drug": [
{
"text": "heparin",
"start": 37,
"end": 44
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"tex... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Priapism as a complication of heparin therapy. | {
"entities": {
"adverse effect": [
{
"text": "Priapism",
"start": 0,
"end": 8
}
],
"drug": [
{
"text": "heparin",
"start": 30,
"end": 37
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect. | {
"entities": {
"drug": [
{
"text": "heparin",
"start": 24,
"end": 31
}
],
"adverse effect": [
{
"text": "priapism",
"start": 36,
"end": 44
},
{
"text": "abnormal platelet aggregation",
"start": 66,
"end"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine. | {
"entities": {
"adverse effect": [
{
"text": "neutropenia",
"start": 32,
"end": 43
},
{
"text": "agranulocytosis",
"start": 48,
"end": 63
}
],
"drug": [
{
"text": "clozapine",
"start": 117,
"end": 126
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC). | {
"entities": {
"drug": [
{
"text": "clozapine",
"start": 60,
"end": 69
}
],
"adverse effect": [
{
"text": "diurnal variation of the white blood cells",
"start": 121,
"end": 163
}
]
},
"relations": {
"adverse effect": [
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukemia. | {
"entities": {
"adverse effect": [
{
"text": "Acute neutrophilic dermatosis",
"start": 0,
"end": 29
}
],
"drug": [
{
"text": "all-trans-retinoic acid",
"start": 41,
"end": 64
}
]
},
"relations": {
"adverse effect": [
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine. | {
"entities": {
"adverse effect": [
{
"text": "hair loss",
"start": 78,
"end": 87
}
],
"drug": [
{
"text": "paroxetine",
"start": 113,
"end": 123
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Hair loss associated with paroxetine treatment: a case report. | {
"entities": {
"adverse effect": [
{
"text": "Hair loss",
"start": 0,
"end": 9
}
],
"drug": [
{
"text": "paroxetine",
"start": 26,
"end": 36
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report on a 37-year-old female who complained of moderate hair loss during paroxetine treatment. | {
"entities": {
"adverse effect": [
{
"text": "hair loss",
"start": 61,
"end": 70
}
],
"drug": [
{
"text": "paroxetine",
"start": 78,
"end": 88
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSION: Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy. | {
"entities": {
"drug": [
{
"text": "insulin",
"start": 26,
"end": 33
}
],
"adverse effect": [
{
"text": "protamine allergy",
"start": 170,
"end": 187
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose. | {
"entities": {
"drug": [
{
"text": "insulin",
"start": 30,
"end": 37
},
{
"text": "insulin",
"start": 131,
"end": 138
}
],
"adverse effect": [
{
"text": "severe urticaria",
"start": 58,
"end": 74
}... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin. | {
"entities": {
"drug": [
{
"text": "NPH insulin",
"start": 81,
"end": 92
},
{
"text": "insulin",
"start": 114,
"end": 121
}
],
"adverse effect": [
{
"text": "allergic symptoms",
"start": 153,
"end": 170
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Patients receiving neutral protamine Hagedorn (NPH) insulin are at increased risk for the development of protamine hypersensitivity. | {
"entities": {
"drug": [
{
"text": "neutral protamine Hagedorn (NPH) insulin",
"start": 19,
"end": 59
}
],
"adverse effect": [
{
"text": "protamine hypersensitivity",
"start": 105,
"end": 131
}
]
},
"relations": {
"advers... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Protamine allergy as a complication of insulin hypersensitivity: A case report. | {
"entities": {
"adverse effect": [
{
"text": "Protamine allergy",
"start": 0,
"end": 17
}
],
"drug": [
{
"text": "insulin",
"start": 39,
"end": 46
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
She continued to receive regular insulin 4 times per day over the following 3 years with only occasional hives. | {
"entities": {
"drug": [
{
"text": "insulin",
"start": 33,
"end": 40
}
],
"adverse effect": [
{
"text": "hives",
"start": 105,
"end": 110
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin. | {
"entities": {
"adverse effect": [
{
"text": "urticaria",
"start": 30,
"end": 39
},
{
"text": "angioedema",
"start": 44,
"end": 54
}
],
"drug": [
{
"text": "NPH",
"start": 99,
"end": 102
},
{... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A 5-month-old infant became lethargic and poorly responsive after receiving 1 drop of brimonidine in each eye. | {
"entities": {
"adverse effect": [
{
"text": "lethargic",
"start": 28,
"end": 37
},
{
"text": "poorly responsive",
"start": 42,
"end": 59
}
],
"drug": [
{
"text": "brimonidine",
"start": 86,
"end": 97
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
An 11-day-old infant became lethargic and apneic after a single drop of brimonidine. | {
"entities": {
"adverse effect": [
{
"text": "lethargic",
"start": 28,
"end": 37
},
{
"text": "apneic",
"start": 42,
"end": 48
}
],
"drug": [
{
"text": "brimonidine",
"start": 72,
"end": 83
}
]... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Apparent central nervous system depression in infants after the use of topical brimonidine. | {
"entities": {
"adverse effect": [
{
"text": "central nervous system depression",
"start": 9,
"end": 42
}
],
"drug": [
{
"text": "brimonidine",
"start": 79,
"end": 90
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSIONS: Topical brimonidine may be associated with central nervous system depression in infants. | {
"entities": {
"drug": [
{
"text": "brimonidine",
"start": 21,
"end": 32
}
],
"adverse effect": [
{
"text": "central nervous system depression",
"start": 56,
"end": 89
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
PURPOSE: To report two cases in which topical brimonidine resulted in apparent central nervous system depression and unresponsiveness in an infant. | {
"entities": {
"drug": [
{
"text": "brimonidine",
"start": 46,
"end": 57
}
],
"adverse effect": [
{
"text": "central nervous system depression",
"start": 79,
"end": 112
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis. | {
"entities": {
"drug": [
{
"text": "ceftriaxone",
"start": 126,
"end": 137
}
],
"adverse effect": [
{
"text": "elevated hepato-biliary enzymes",
"start": 143,
"end": 174
},
{
"text": "transient biliary stasis",
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Hepato-biliary abnormalities secondary to ceftriaxone use: a case report. | {
"entities": {
"adverse effect": [
{
"text": "Hepato-biliary abnormalities",
"start": 0,
"end": 28
}
],
"drug": [
{
"text": "ceftriaxone",
"start": 42,
"end": 53
}
]
},
"relations": {
"adverse effect": [
{
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. | {
"entities": {
"adverse effect": [
{
"text": "Anterior lumbosacral radiculopathy",
"start": 0,
"end": 34
}
],
"drug": [
{
"text": "methotrexate",
"start": 53,
"end": 65
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery. | {
"entities": {
"adverse effect": [
{
"text": "progressive paraparesis",
"start": 42,
"end": 65
}
],
"drug": [
{
"text": "methotrexate",
"start": 84,
"end": 96
}
]
},
"relations": {
"adverse effect": [
{
"hea... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes. | {
"entities": {
"drug": [
{
"text": "arsenic trioxide",
"start": 25,
"end": 41
}
],
"adverse effect": [
{
"text": "decrease in the D-dimers",
"start": 60,
"end": 84
},
{
"text": "slight decrease in peripheral blood leuko... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne. | {
"entities": {
"adverse effect": [
{
"text": "fever",
"start": 34,
"end": 39
},
{
"text": "chills",
"start": 41,
"end": 47
},
{
"text": "fatigue",
"start": 49,
"end": 56
},
{
"text": "night s... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis-like syndrome produced by the minocycline ingestion. | {
"entities": {
"adverse effect": [
{
"text": "mononucleosis-like syndrome",
"start": 96,
"end": 123
}
],
"drug": [
{
"text": "minocycline",
"start": 140,
"end": 151
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We conclude that the presence of this metabolic defect combined with topical 5-FU (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of life-threatening toxicity after treatment with a topical drug. | {
"entities": {
"drug": [
{
"text": "5-FU",
"start": 77,
"end": 81
}
],
"adverse effect": [
{
"text": "life-threatening toxicity",
"start": 171,
"end": 196
}
]
},
"relations": {
"adverse effect": [
{
"head": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We now report the first known cancer patient who developed life-threatening complications after treatment with topical 5-FU and was shown subsequently to have profound DPD deficiency. | {
"entities": {
"adverse effect": [
{
"text": "life-threatening complications",
"start": 59,
"end": 89
}
],
"drug": [
{
"text": "5-FU",
"start": 119,
"end": 123
}
]
},
"relations": {
"adverse effect": [
{
"he... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms. | {
"entities": {
"adverse effect": [
{
"text": "acute ischaemic event",
"start": 3,
"end": 24
}
],
"drug": [
{
"text": "venlafaxine",
"start": 52,
"end": 63
}
]
},
"relations": {
"adverse effect": [
{
"head": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties. | {
"entities": {
"drug": [
{
"text": "venlafaxine",
"start": 19,
"end": 30
}
],
"adverse effect": [
{
"text": "ischaemic events",
"start": 46,
"end": 62
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
This is the first report of a possible association between an acute cardiovascular event and venlafaxine. | {
"entities": {
"adverse effect": [
{
"text": "acute cardiovascular event",
"start": 62,
"end": 88
}
],
"drug": [
{
"text": "venlafaxine",
"start": 93,
"end": 104
}
]
},
"relations": {
"adverse effect": [
{
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with venlafaxine, and developed acute myocardial ischaemia within the first week of treatment. | {
"entities": {
"drug": [
{
"text": "venlafaxine",
"start": 115,
"end": 126
}
],
"adverse effect": [
{
"text": "acute myocardial ischaemia",
"start": 142,
"end": 168
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? | {
"entities": {
"drug": [
{
"text": "cyclophosphamide",
"start": 9,
"end": 25
}
],
"adverse effect": [
{
"text": "embryopathy",
"start": 36,
"end": 47
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype. | {
"entities": {
"drug": [
{
"text": "CP",
"start": 65,
"end": 67
},
{
"text": "CP",
"start": 141,
"end": 143
}
],
"adverse effect": [
{
"text": "multiple congenital anomalies",
"start": 82,
"end": 111
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. | {
"entities": {
"drug": [
{
"text": "cyclosposphamide",
"start": 43,
"end": 59
}
],
"adverse effect": [
{
"text": "developmental delay",
"start": 133,
"end": 152
},
{
"text": "craniosynostosis",
"start": 154,
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We conclude that (a) cyclophosphamide is a human teratogen, (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question. | {
"entities": {
"drug": [
{
"text": "cyclophosphamide",
"start": 21,
"end": 37
}
],
"adverse effect": [
{
"text": "human teratogen",
"start": 43,
"end": 58
}
]
},
"relations": {
"adverse effect": [
{
"head": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
In all cases, seizures were controlled by withdrawal of phenytoin and reduction of drug levels. | {
"entities": {
"adverse effect": [
{
"text": "seizures",
"start": 14,
"end": 22
}
],
"drug": [
{
"text": "phenytoin",
"start": 56,
"end": 65
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Paradoxical seizures in phenytoin toxicity. | {
"entities": {
"adverse effect": [
{
"text": "seizures",
"start": 12,
"end": 20
}
],
"drug": [
{
"text": "phenytoin",
"start": 24,
"end": 33
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We present three patients with paradoxical seizures; their serum phenytoin levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL. | {
"entities": {
"adverse effect": [
{
"text": "seizures",
"start": 43,
"end": 51
}
],
"drug": [
{
"text": "phenytoin",
"start": 65,
"end": 74
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms. | {
"entities": {
"drug": [
{
"text": "losartan",
"start": 37,
"end": 45
}
],
"adverse effect": [
{
"text": "angioedema",
"start": 68,
"end": 78
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Losartan-induced angioedema. | {
"entities": {
"drug": [
{
"text": "Losartan",
"start": 0,
"end": 8
}
],
"adverse effect": [
{
"text": "angioedema",
"start": 17,
"end": 27
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"te... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
OBJECTIVE: To report a case of angioedema associated with losartan administration. | {
"entities": {
"adverse effect": [
{
"text": "angioedema",
"start": 31,
"end": 41
}
],
"drug": [
{
"text": "losartan",
"start": 58,
"end": 66
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown. | {
"entities": {
"adverse effect": [
{
"text": "angioedema",
"start": 17,
"end": 27
}
],
"drug": [
{
"text": "losartan",
"start": 41,
"end": 49
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis. | {
"entities": {
"adverse effect": [
{
"text": "hepatic adenomas",
"start": 68,
"end": 84
}
],
"drug": [
{
"text": "danazol",
"start": 105,
"end": 112
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy. | {
"entities": {
"drug": [
{
"text": "Heparin",
"start": 0,
"end": 7
}
],
"adverse effect": [
{
"text": "thrombocytopenia",
"start": 16,
"end": 32
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran). | {
"entities": {
"drug": [
{
"text": "heparin",
"start": 10,
"end": 17
}
],
"adverse effect": [
{
"text": "thrombocytopenia",
"start": 26,
"end": 42
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children. | {
"entities": {
"drug": [
{
"text": "heparin",
"start": 147,
"end": 154
}
],
"adverse effect": [
{
"text": "thrombocytopenia",
"start": 163,
"end": 179
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran). | {
"entities": {
"drug": [
{
"text": "heparin",
"start": 38,
"end": 45
}
],
"adverse effect": [
{
"text": "thrombocytopenia",
"start": 54,
"end": 70
},
{
"text": "hemorrhagic complications",
"start": 86,
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Taxane-induced glaucoma. | {
"entities": {
"drug": [
{
"text": "Taxane",
"start": 0,
"end": 6
}
],
"adverse effect": [
{
"text": "glaucoma",
"start": 15,
"end": 23
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text":... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report a case of glaucoma induced by doxetaxel therapy for metastatic breast cancer. | {
"entities": {
"adverse effect": [
{
"text": "glaucoma",
"start": 20,
"end": 28
}
],
"drug": [
{
"text": "doxetaxel",
"start": 40,
"end": 49
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure. | {
"entities": {
"adverse effect": [
{
"text": "hyperphosphatemia",
"start": 6,
"end": 23
}
],
"drug": [
{
"text": "sodium phosphate",
"start": 34,
"end": 50
}
]
},
"relations": {
"adverse effect": [
{
"head":... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema). | {
"entities": {
"adverse effect": [
{
"text": "hyperphosphatemia",
"start": 26,
"end": 43
}
],
"drug": [
{
"text": "sodium phosphate",
"start": 82,
"end": 98
},
{
"text": "sodium biphosphate",
"start": 103,
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
ADE Corpus
ADE Corpus (end-to-end relation extraction), rebuilt for MNEB from the original release with character-level offsets.
Source: ADE corpus v2 DRUG-AE.rel (https://github.com/trunghlt/AdverseDrugReaction)
| config | split | records |
|---|---|---|
| default | test | 4272 |
Labels
entities: drug, adverse effect
relations: adverse effect
Format
Each record has input (the text), output (gold annotations grouped by label) and schema (the label set with descriptions). Offsets are character offsets into input, half-open [start, end).
"output": {
"entities": {"<label>": [{"text", "start", "end"}]},
"relations": {"<label>": [{"head": {"text", "start", "end"},
"tail": {"text", "start", "end"}}]},
"events": {"<label>": [{"trigger": {"text", "start", "end"},
"arguments": [{"role", "text", "start", "end"}]}]}
}
Each schema item has a description and a description_source: official when adapted from the dataset's paper or guideline, mneb when written for MNEB. Relation datasets also give setting (end_to_end or gold_entity) and negative_label; relation items give symmetric. Event items list the roles valid for that event type.
Within a record, identical annotations are kept once and outer whitespace is trimmed from spans; source annotations are otherwise kept as annotated.
Notes
- The corpus has no official split, so all 4,272 sentences are published as
test. - Text is the original sentence. Head = adverse effect, tail = drug.
Build
Built by scripts/datasets/ade.py in the MNEB repository.
Citation
Gurulingappa et al. (2012), Development of a benchmark corpus to support the automatic extraction of drug-related adverse effects from medical case reports. J. Biomed. Inform.
License: not stated by the source; see the original release.
- Downloads last month
- 85